Terms: = Liver cancer AND PALB2, ENSG00000083093, 79728 AND Treatment
3 results:
1. Prevalence and Risk Factors of Germline Pathogenic Variants in Pancreatic Ductal Adenocarcinoma.
Ryu KH; Park S; Chun JW; Cho E; Choi J; Lee DE; Shim H; Kim YH; Han SS; Park SJ; Woo SM; Kong SY
Cancer Res Treat; 2023 Oct; 55(4):1303-1312. PubMed ID: 37024097
[TBL] [Abstract] [Full Text] [Related]
2. Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or palb2 mutation.
Wattenberg MM; Asch D; Yu S; O'Dwyer PJ; Domchek SM; Nathanson KL; Rosen MA; Beatty GL; Siegelman ES; Reiss KA
Br J Cancer; 2020 Feb; 122(3):333-339. PubMed ID: 31787751
[TBL] [Abstract] [Full Text] [Related]
3. Response to olaparib in a
Horak P; Weischenfeldt J; von Amsberg G; Beyer B; Schütte A; Uhrig S; Gieldon L; Klink B; Feuerbach L; Hübschmann D; Kreutzfeldt S; Heining C; Maier S; Hutter B; Penzel R; Schlesner M; Eils R; Sauter G; Stenzinger A; Brors B; Schröck E; Glimm H; Fröhling S; Schlomm T
Cold Spring Harb Mol Case Stud; 2019 Apr; 5(2):. PubMed ID: 30833416
[TBL] [Abstract] [Full Text] [Related]
